248 related articles for article (PubMed ID: 34895481)
21. The impact of antibiotic use on clinical features and survival outcomes of cancer patients treated with immune checkpoint inhibitors.
Zhou J; Huang G; Wong WC; Hu DH; Zhu JW; Li R; Zhou H
Front Immunol; 2022; 13():968729. PubMed ID: 35967438
[TBL] [Abstract][Full Text] [Related]
22. Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer.
Kawachi H; Yamada T; Tamiya M; Negi Y; Goto Y; Nakao A; Shiotsu S; Tanimura K; Takeda T; Okada A; Harada T; Date K; Chihara Y; Hasegawa I; Tamiya N; Ishida M; Katayama Y; Morimoto K; Iwasaku M; Tokuda S; Kijima T; Takayama K
JAMA Netw Open; 2023 Jul; 6(7):e2322915. PubMed ID: 37432682
[TBL] [Abstract][Full Text] [Related]
23. HLA-I levels correlate with survival outcomes in response to immune checkpoint inhibitors in non-small cell lung cancer.
Saigí M; Mate JL; Carcereny E; Martínez-Cardús A; Esteve A; Andreo F; Centeno C; Cucurull M; Mesia R; Pros E; Sanchez-Cespedes M
Lung Cancer; 2024 Mar; 189():107502. PubMed ID: 38359742
[TBL] [Abstract][Full Text] [Related]
24. Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study.
Lee CH; Shah AY; Rasco D; Rao A; Taylor MH; Di Simone C; Hsieh JJ; Pinto A; Shaffer DR; Girones Sarrio R; Cohn AL; Vogelzang NJ; Bilen MA; Gunnestad Ribe S; Goksel M; Tennøe ØK; Richards D; Sweis RF; Courtright J; Heinrich D; Jain S; Wu J; Schmidt EV; Perini RF; Kubiak P; Okpara CE; Smith AD; Motzer RJ
Lancet Oncol; 2021 Jul; 22(7):946-958. PubMed ID: 34143969
[TBL] [Abstract][Full Text] [Related]
25. Immunotherapy-Mediated Thyroid Dysfunction: Genetic Risk and Impact on Outcomes with PD-1 Blockade in Non-Small Cell Lung Cancer.
Luo J; Martucci VL; Quandt Z; Groha S; Murray MH; Lovly CM; Rizvi H; Egger JV; Plodkowski AJ; Abu-Akeel M; Schulze I; Merghoub T; Cardenas E; Huntsman S; Li M; Hu D; Gubens MA; Gusev A; Aldrich MC; Hellmann MD; Ziv E
Clin Cancer Res; 2021 Sep; 27(18):5131-5140. PubMed ID: 34244291
[TBL] [Abstract][Full Text] [Related]
26. Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study.
Sanchez A; Furberg H; Kuo F; Vuong L; Ged Y; Patil S; Ostrovnaya I; Petruzella S; Reising A; Patel P; Mano R; Coleman J; Russo P; Liu CH; Dannenberg AJ; Chan TA; Motzer R; Voss MH; Hakimi AA
Lancet Oncol; 2020 Feb; 21(2):283-293. PubMed ID: 31870811
[TBL] [Abstract][Full Text] [Related]
27. Germline HLA-B evolutionary divergence influences the efficacy of immune checkpoint blockade therapy in gastrointestinal cancer.
Lu Z; Chen H; Jiao X; Wang Y; Wu L; Sun H; Li S; Gong J; Li J; Zou J; Yang K; Hu Y; Mao B; Zhang L; Zhang X; Peng Z; Lu M; Wang Z; Zhang H; Shen L
Genome Med; 2021 Nov; 13(1):175. PubMed ID: 34732240
[TBL] [Abstract][Full Text] [Related]
28. Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial.
Monk BJ; Colombo N; Oza AM; Fujiwara K; Birrer MJ; Randall L; Poddubskaya EV; Scambia G; Shparyk YV; Lim MC; Bhoola SM; Sohn J; Yonemori K; Stewart RA; Zhang X; Perkins Smith J; Linn C; Ledermann JA
Lancet Oncol; 2021 Sep; 22(9):1275-1289. PubMed ID: 34363762
[TBL] [Abstract][Full Text] [Related]
29. Comprehensive molecular analysis identifies RET alterations association with response of ICIs in multi-immunotherapy cohorts.
Long JY; Li RZ; Wang DX; Liu H; Tian J; Ding ZN; Yan LJ; Dong ZR; Hong JG; Tian BW; Han CL; Zhao HT; Li T
Int Immunopharmacol; 2024 Jan; 126():111281. PubMed ID: 38061115
[TBL] [Abstract][Full Text] [Related]
30. Alteration in TET1 as potential biomarker for immune checkpoint blockade in multiple cancers.
Wu HX; Chen YX; Wang ZX; Zhao Q; He MM; Wang YN; Wang F; Xu RH
J Immunother Cancer; 2019 Oct; 7(1):264. PubMed ID: 31623662
[TBL] [Abstract][Full Text] [Related]
31. Immune related endonucleases and GTPases are not associated with tumor response in patients with advanced non-small cell lung cancer treated with checkpoint inhibitors.
Ramdani HO; Falk M; Heukamp LC; Schatz S; Tiemann M; Wesseler C; Diehl L; Schuuring E; Groen HJM; Griesinger F
Pathol Res Pract; 2021 Nov; 227():153651. PubMed ID: 34673351
[TBL] [Abstract][Full Text] [Related]
32. Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: A systematic review and meta-analysis.
Zheng J; Shao M; Yang W; Ren J; Chen X; Yang H
Int Immunopharmacol; 2022 Nov; 112():109244. PubMed ID: 36126410
[TBL] [Abstract][Full Text] [Related]
33. Genomic correlates of response and resistance to immune checkpoint inhibitors in carcinomas of unknown primary.
Rassy E; Boussios S; Pavlidis N
Eur J Clin Invest; 2021 Sep; 51(9):e13583. PubMed ID: 33970501
[TBL] [Abstract][Full Text] [Related]
34. Association of tumour burden with the efficacy of programmed cell death-1/programmed cell death ligand-1 inhibitors for treatment-naïve advanced non-small-cell lung cancer.
Suzuki S; Haratani K; Hayashi H; Chiba Y; Tanizaki J; Kato R; Mitani S; Kawanaka Y; Kurosaki T; Hasegawa Y; Okabe T; Tanaka K; Akashi Y; Ozaki T; Nishio K; Ito A; Nakagawa K
Eur J Cancer; 2022 Jan; 161():44-54. PubMed ID: 34922263
[TBL] [Abstract][Full Text] [Related]
35. Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study.
Pujade-Lauraine E; Fujiwara K; Ledermann JA; Oza AM; Kristeleit R; Ray-Coquard IL; Richardson GE; Sessa C; Yonemori K; Banerjee S; Leary A; Tinker AV; Jung KH; Madry R; Park SY; Anderson CK; Zohren F; Stewart RA; Wei C; Dychter SS; Monk BJ
Lancet Oncol; 2021 Jul; 22(7):1034-1046. PubMed ID: 34143970
[TBL] [Abstract][Full Text] [Related]
36. PTPRD/PTPRT mutation as a predictive biomarker of immune checkpoint inhibitors across multiple cancer types.
Shang X; Zhang W; Zhang X; Yu M; Liu J; Cheng Y; Cheng B
Front Immunol; 2022; 13():991091. PubMed ID: 36248841
[TBL] [Abstract][Full Text] [Related]
37. Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors.
Abou Alaiwi S; Nassar AH; Xie W; Bakouny Z; Berchuck JE; Braun DA; Baca SC; Nuzzo PV; Flippot R; Mouhieddine TH; Spurr LF; Li YY; Li T; Flaifel A; Steinharter JA; Margolis CA; Vokes NI; Du H; Shukla SA; Cherniack AD; Sonpavde G; Haddad RI; Awad MM; Giannakis M; Hodi FS; Liu XS; Signoretti S; Kadoch C; Freedman ML; Kwiatkowski DJ; Van Allen EM; Choueiri TK
Cancer Immunol Res; 2020 Aug; 8(8):1075-1084. PubMed ID: 32321774
[TBL] [Abstract][Full Text] [Related]
38. mTOR pathway gene mutations predict response to immune checkpoint inhibitors in multiple cancers.
Cheng L; Wang Y; Qiu L; Chang Y; Lu H; Liu C; Zhang B; Zhou Y; Bai H; Xiong L; Zhong H; Nie W; Han B
J Transl Med; 2022 May; 20(1):247. PubMed ID: 35642038
[TBL] [Abstract][Full Text] [Related]
39. Effectiveness of Immune Checkpoint Inhibitors in Patients With Advanced Esophageal Squamous Cell Carcinoma: A Meta-analysis Including Low PD-L1 Subgroups.
Yap DWT; Leone AG; Wong NZH; Zhao JJ; Tey JCS; Sundar R; Pietrantonio F
JAMA Oncol; 2023 Feb; 9(2):215-224. PubMed ID: 36480211
[TBL] [Abstract][Full Text] [Related]
40. Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma.
Jang SR; Nikita N; Banks J; Keith SW; Johnson JM; Wilson M; Lu-Yao G
JAMA Netw Open; 2021 Dec; 4(12):e2136823. PubMed ID: 34854905
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]